{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:02:58Z","timestamp":1790744578194,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s40264-020-00953-0","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T05:02:41Z","timestamp":1591851761000},"page":"611-614","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Does Ibuprofen Worsen COVID-19?"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1212-2817","authenticated-orcid":false,"given":"Nicholas","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Carleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Blin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Bosco-Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Droz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,11]]},"reference":[{"key":"953_CR1","unstructured":"Le ministre de la sant\u00e9 d\u00e9conseille l\u2019ibuprof\u00e8ne contre le coronavirus. Le Monda. 2020 March 14. https:\/\/www.lemonde.fr\/societe\/article\/2020\/03\/14\/face-au-coronavirus-le-ministre-de-la-sante-recommande-de-ne-pas-prendre-d-ibuprofene_6033095_3224.html."},{"key":"953_CR2","unstructured":"DGS-urgent. Liste des messages d\u2019alertes. https:\/\/dgs-urgent.sante.gouv.fr\/dgsurgent\/inter\/detailsMessageBuilder.do;jsessionid=21ECACBF8B1ECE6C542B9126E7A8215F.du-dgsurgentc2?id=30500&cmd=visualiserMessage."},{"key":"953_CR3","unstructured":"Bosredon M. Video: Coronavirus \u00e0 Bordeaux: Au c\u0153ur de l\u2019unit\u00e9 Covid-19 du service r\u00e9animation du CHU Pellegrin. https:\/\/www.20minutes.fr\/societe\/2742271-20200317-coronavirus-bordeaux-ur-unite-covid-19-service-reanimation-chu-pellegrin."},{"issue":"4","key":"953_CR4","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","volume":"8","author":"L Fang","year":"2020","unstructured":"Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. https:\/\/doi.org\/10.1016\/S2213-2600(20)30116-8.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"953_CR5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271\u201380.","journal-title":"Cell"},{"key":"953_CR6","doi-asserted-by":"publisher","first-page":"m1185","DOI":"10.1136\/bmj.m1185","volume":"368","author":"P Little","year":"2020","unstructured":"Little P. Non-steroidal anti-inflammatory drugs and covid-19. BMJ. 2020;368:m1185.","journal-title":"BMJ"},{"key":"953_CR7","doi-asserted-by":"publisher","first-page":"m1086","DOI":"10.1136\/bmj.m1086","volume":"368","author":"M Day","year":"2020","unstructured":"Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ. 2020;368:m1086.","journal-title":"BMJ"},{"key":"953_CR8","doi-asserted-by":"publisher","first-page":"m1168","DOI":"10.1136\/bmj.m1168","volume":"368","author":"M Day","year":"2020","unstructured":"Day M. Covid-19: European drugs agency to review safety of ibuprofen. BMJ. 2020;368:m1168.","journal-title":"BMJ"},{"key":"953_CR9","unstructured":"Agence nationale de securite du medicament et des produits de sante. Usage des m\u00e9dicaments en ville durant l\u2019\u00e9pid\u00e9mie de Covid-19: point de situation apr\u00e8s cinq semaines de confinement\u2014Point d'information. https:\/\/www.ansm.sante.fr\/S-informer\/Points-d-information-Points-d-information\/Usage-des-medicaments-en-ville-durant-l-epidemie-de-Covid-19-point-de-situation-apres-cinq-semaines-de-confinement-Point-d-information."},{"key":"953_CR10","unstructured":"European Medicines Agency. EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19. London: EMA; 2020 March 18. https:\/\/www.ema.europa.eu\/en\/news\/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19."},{"key":"953_CR11","unstructured":"Updated: WHO Now Doesn't Recommend Avoiding Ibuprofen For COVID-19 Symptoms. https:\/\/www.sciencealert.com\/who-recommends-to-avoid-taking-ibuprofen-for-covid-19-symptoms."},{"key":"953_CR12","doi-asserted-by":"publisher","first-page":"m1555","DOI":"10.1136\/bmj.m1555","volume":"369","author":"I Torjesen","year":"2020","unstructured":"Torjesen I. Covid-19: ibuprofen can be used for symptoms, says UK agency, but reasons for change in advice are unclear. BMJ. 2020;369:m1555.","journal-title":"BMJ"},{"key":"953_CR13","unstructured":"Capuano A, Scaglione F, Berrino L, Del Re M, Bernardini R, Chiamulera C, et al. Official statement of the section of Clinical Pharmacology of Italian Society of Pharmacology on Non-steroidal anti-inflammatory drugs (NSAIDs) and the increased risk of complications during infections with commentary. Pharmadvances 2020; 2(1):6\u201310. https:\/\/www.pharmadvances.com\/official-statement-of-the-section-of-clinical-pharmacology-of-italian-society-of-pharmacology-on-non-steroidal-anti-inflammatory-drugs-nsaids-and-the-increased-risk-of-complications-during-infection-2\/."},{"key":"953_CR14","doi-asserted-by":"crossref","unstructured":"Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94(7).","DOI":"10.1128\/JVI.00127-20"},{"issue":"2","key":"953_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000375362","volume":"131","author":"W Qiao","year":"2015","unstructured":"Qiao W, Wang C, Chen B, Zhang F, Liu Y, Lu Q, et al. Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats. Cardiology. 2015;131(2):97\u2013106.","journal-title":"Cardiology"},{"key":"953_CR16","unstructured":"Freund A. Coronavirus confusion about safety of ibuprofen. 2020 March 20. https:\/\/www.dw.com\/en\/coronavirus-confusion-about-safety-of-ibuprofen\/a-52824043."},{"key":"953_CR17","doi-asserted-by":"publisher","first-page":"f6041","DOI":"10.1136\/bmj.f6041","volume":"347","author":"P Little","year":"2013","unstructured":"Little P, Moore M, Kelly J, Williamson I, Leydon G, McDermott L, et al. Ibuprofen, paracetamol, and steam for patients with respiratory tract infections in primary care: pragmatic randomised factorial trial. BMJ. 2013;347:f6041.","journal-title":"BMJ"},{"key":"953_CR18","doi-asserted-by":"crossref","unstructured":"Voiriot G, Philippot Q, Elabbadi A, Elbim C, Chalumeau M, Fartoukh M. Risks related to the use of non-steroidal anti-inflammatory drugs in community-acquired pneumonia in adult and pediatric patients. J Clin Med. 2019;8(6).","DOI":"10.3390\/jcm8060786"},{"issue":"1","key":"953_CR19","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1164\/rccm.201802-0229LE","volume":"198","author":"D Basille","year":"2018","unstructured":"Basille D, Thomsen RW, Madsen M, Duhaut P, Andrejak C, Jounieaux V, et al. Nonsteroidal antiinflammatory drug use and clinical outcomes of community-acquired pneumonia. Am J Respir Crit Care Med. 2018;198(1):128\u201331.","journal-title":"Am J Respir Crit Care Med"},{"issue":"19","key":"953_CR20","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1093\/eurheartj\/ehaa235","volume":"41","author":"GM Kuster","year":"2020","unstructured":"Kuster GM, Pfister O, Burkard T, Zhou Q, Twerenbold R, Haaf P, et al. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? Eur Heart J. 2020;41(19):1801\u20133.","journal-title":"Eur Heart J"},{"key":"953_CR21","doi-asserted-by":"crossref","unstructured":"Trifiro G, Crisafulli S, Ando G, Racagni G, Drago F, Italian Society of Pharmacology. Should patients receiving ACE inhibitors or angiotensin receptor blockers be switched to other antihypertensive drugs to prevent or improve prognosis of novel coronavirus disease 2019 (COVID-19)? Drug Saf. 2020;43(6):507\u2013509.","DOI":"10.1007\/s40264-020-00935-2"},{"key":"953_CR22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2006923","author":"G Mancia","year":"2020","unstructured":"Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMoa2006923.","journal-title":"N Engl J Med"},{"key":"953_CR23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008975","author":"HR Reynolds","year":"2020","unstructured":"Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMoa2008975.","journal-title":"N Engl J Med"},{"key":"953_CR24","doi-asserted-by":"crossref","unstructured":"Ip A, Parikh K, Parrillo JE, Mathura S, Hansen E, Sawczuk IS, et al. Hypertension and renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. medRxiv. 2020:2020.04.24.20077388.","DOI":"10.1101\/2020.04.24.20077388"},{"issue":"17","key":"953_CR25","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","volume":"382","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382(17):1653\u20139. https:\/\/doi.org\/10.1056\/NEJMsr2005760.","journal-title":"N Engl J Med"},{"key":"953_CR26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2012924","author":"JA Jarcho","year":"2020","unstructured":"Jarcho JA, Ingelfinger JR, Hamel MB, D'Agostino RB Sr, Harrington DP. Inhibitors of the renin-angiotensin-aldosterone system and Covid-19. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMe2012924.","journal-title":"N Engl J Med"},{"key":"953_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-020-01890-6","author":"O Zolk","year":"2020","unstructured":"Zolk O, Hafner S, Schmidt CQ, German Society for Experimental, and Clinical Pharmacology, and Toxicology. COVID-19 pandemic and therapy with ibuprofen or renin-angiotensin system blockers: no need for interruptions or changes in ongoing chronic treatments. Naunyn Schmiedebergs Arch Pharmacol. 2020. https:\/\/doi.org\/10.1007\/s00210-020-01890-6.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"953_CR28","doi-asserted-by":"crossref","unstructured":"Castro VM, Ross RA, McBride SM, Perlis RH. Identifying common pharmacotherapies associated with reduced COVID-19 morbidity using electronic health records. medRxiv. 2020:2020.04.11.20061994.","DOI":"10.1101\/2020.04.11.20061994"},{"key":"953_CR29","first-page":"1022","volume":"14","author":"B Russell","year":"2020","unstructured":"Russell B, Moss C, George G, Santaolalla A, Cope A, Papa S, et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience. 2020;14:1022.","journal-title":"Ecancermedicalscience"},{"key":"953_CR30","first-page":"1023","volume":"14","author":"B Russell","year":"2020","unstructured":"Russell B, Moss C, Rigg A, Van Hemelrijck M. COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? Ecancermedicalscience. 2020;14:1023.","journal-title":"Ecancermedicalscience"},{"issue":"4","key":"953_CR31","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40264-018-0752-1","volume":"42","author":"N Moore","year":"2019","unstructured":"Moore N, Duret S, Grolleau A, Lassalle R, Barbet V, Duong M, et al. Previous drug exposure in patients hospitalised for acute liver injury: a case-population study in the French National Healthcare Data System. Drug Saf. 2019;42(4):559\u201372.","journal-title":"Drug Saf"},{"issue":"2","key":"953_CR32","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/bcp.12957","volume":"82","author":"M Duong","year":"2016","unstructured":"Duong M, Gulmez SE, Salvo F, Abouelfath A, Lassalle R, Droz C, et al. Usage patterns of paracetamol in France. Br J Clin Pharmacol. 2016;82(2):498\u2013503.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"953_CR33","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/bcp.12239","volume":"77","author":"M Duong","year":"2014","unstructured":"Duong M, Salvo F, Pariente A, Abouelfath A, Lassalle R, Droz C, et al. Usage patterns of 'over-the-counter' vs prescription-strength nonsteroidal anti-inflammatory drugs in France. Br J Clin Pharmacol. 2014;77(5):887\u201395.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"953_CR34","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1542\/peds.107.5.1108","volume":"107","author":"SM Lesko","year":"2001","unstructured":"Lesko SM, O'Brien KL, Schwartz B, Vezina R, Mitchell AA. Invasive group A streptococcal infection and nonsteroidal antiinflammatory drug use among children with primary varicella. Pediatrics. 2001;107(5):1108\u201315.","journal-title":"Pediatrics"},{"issue":"10","key":"953_CR35","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","volume":"30","author":"A Pariente","year":"2007","unstructured":"Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf. 2007;30(10):891\u20138.","journal-title":"Drug Saf"},{"key":"953_CR36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2005396","author":"SC Chung","year":"2020","unstructured":"Chung SC, Providencia R, Sofat R. Association between angiotensin blockade and incidence of influenza in the United Kingdom. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMc2005396.","journal-title":"N Engl J Med"},{"issue":"5","key":"953_CR37","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","volume":"8","author":"X Yang","year":"2020","unstructured":"Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475\u201381. https:\/\/doi.org\/10.1016\/S2213-2600(20)30079-5.","journal-title":"Lancet Respir Med"},{"key":"953_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/all.14238","author":"JJ Zhang","year":"2020","unstructured":"Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan. China Allergy. 2020. https:\/\/doi.org\/10.1111\/all.14238.","journal-title":"China Allergy"},{"issue":"3","key":"953_CR39","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/bcp.12635","volume":"80","author":"SE Gulmez","year":"2015","unstructured":"Gulmez SE, Larrey D, Pageaux GP, Bernuau J, Bissoli F, Horsmans Y, et al. Liver transplant associated with paracetamol overdose: results from the seven-country SALT study. Br J Clin Pharmacol. 2015;80(3):599\u2013606.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"953_CR40","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40264-012-0013-7","volume":"36","author":"SE Gulmez","year":"2013","unstructured":"Gulmez SE, Larrey D, Pageaux GP, Lignot S, Lassalle R, Jove J, et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. Drug Saf. 2013;36(2):135\u201344.","journal-title":"Drug Saf"},{"issue":"11","key":"953_CR41","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/pds.4640","volume":"27","author":"SE Gulmez","year":"2018","unstructured":"Gulmez SE, Unal US, Lassalle R, Chartier A, Grolleau A, Moore N. Risk of hospital admission for liver injury in users of NSAIDs and nonoverdose paracetamol: Preliminary results from the EPIHAM study. Pharmacoepidemiol Drug Saf. 2018;27(11):1174\u201381.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"953_CR42","first-page":"e17","volume":"8","author":"A Rismanbaf","year":"2020","unstructured":"Rismanbaf A, Zarei S. Liver and kidney injuries in COVID-19 and their effects on drug therapy; a Letter to Editor. Arch Acad Emerg Med. 2020;8(1):e17.","journal-title":"Arch Acad Emerg Med"},{"key":"953_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25783","author":"S Wan","year":"2020","unstructured":"Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. Clinical features and treatment of COVID-19 patients in Northeast Chongqing. J Med Virol. 2020. https:\/\/doi.org\/10.1002\/jmv.25783.","journal-title":"J Med Virol"},{"key":"953_CR44","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa247","author":"D Zhao","year":"2020","unstructured":"Zhao D, Yao F, Wang L, Zheng L, Gao Y, Ye J, et al. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. Clin Infect Dis. 2020. https:\/\/doi.org\/10.1093\/cid\/ciaa247.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"953_CR45","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s40264-020-00933-4","volume":"43","author":"N Moore","year":"2020","unstructured":"Moore N. Chloroquine for COVID-19 infection. Drug Saf. 2020;43(5):393\u20134.","journal-title":"Drug Saf"},{"key":"953_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.03.040","author":"M Sodhi","year":"2020","unstructured":"Sodhi M, Etminan M. Safety of ibuprofen in patients with COVID-19: causal or confounded? Chest. 2020. https:\/\/doi.org\/10.1016\/j.chest.2020.03.040.","journal-title":"Chest"},{"key":"953_CR47","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000001196","author":"GK Sridharan","year":"2020","unstructured":"Sridharan GK, Kotagiri R, Chandiramani VH, Mohan BP, Vegunta R, Vegunta R, et al. COVID-19 and avoiding ibuprofen. How good is the evidence? Am J Ther. 2020. https:\/\/doi.org\/10.1097\/MJT.0000000000001196.","journal-title":"Am J Ther"},{"key":"953_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5029","author":"A Pottegard","year":"2020","unstructured":"Pottegard A, Kurz X, Moore N, Christiansen CF, Klungel O. Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic. Pharmacoepidemiol Drug Saf. 2020. https:\/\/doi.org\/10.1002\/pds.5029.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-00953-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-020-00953-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-00953-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T23:32:57Z","timestamp":1623367977000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-020-00953-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,11]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["953"],"URL":"https:\/\/doi.org\/10.1007\/s40264-020-00953-0","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,11]]},"assertion":[{"value":"11 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No sources of funding were used to prepare this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Nicholas Moore has provided expert advice to pharmaceutical companies and regulators concerning risks associated with low-dose NSAIDs and other analgesics over the last\u2009\u2265\u200930\u00a0years. Bruce Carleton, Patrick Blin, Pauline Bosco-Levy, and Cecile Droz have no conflicts of interest that are directly relevant to the content of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}